Document Detail


Randomly allocated study of the effects of standard therapy versus ACE inhibition on micro-albuminuria in essential hypertension.
MedLine Citation:
PMID:  7965276     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To compare the effects of standard therapy (diuretic, beta-blocker or both) with those of angiotensin converting enzyme (ACE) inhibition with quinapril on renal function and urinary albumin excretion in patients with essential hypertension. METHODS: A 1-year, placebo-controlled, randomly allocated study was conducted in a group of 40 patients with essential hypertension. Before beginning the active treatment phase, all patients were given a matched placebo for quinapril for at least 14 days. At baseline and after 1, 3, 6 and 12 months of treatment, blood pressure, heart rate, body weight, renal plasma flow, glomerular filtration rate, plasma renin activity, plasma aldosterone and urinary albumin excretion were measured. RESULTS: Both the standard therapy and quinapril produced similar decreases in blood pressure, but only quinapril produced a significant decrease in micro-albuminuria, from 68.5 +/- 16.7 to 47.2 +/- 14.9 mg/24 h (P < 0.05). The renal plasma flow remained constant in both study groups while the glomerular filtration rate and filtration fraction decreased significantly (P < 0.05) in the quinapril group. CONCLUSIONS: The results of this study indicate that long-term therapy for essential hypertension with ACE inhibition has a more favorable effect on micro-albuminuria than standard therapy for an equal level of blood pressure control.
Authors:
L M Ruilope; V Lahera; J M Alcázar; M Praga; C Campo; J L Rodicio
Related Documents :
8305666 - Angiotensin-converting enzyme inhibitors in cardiovascular anesthesia.
15030296 - Combination therapy with ace inhibitors/angiotensin ii receptor antagonists and diureti...
2992076 - Deterioration of renal function during angiotensin converting enzyme inhibition in hype...
8886426 - Comparison of angiotensin ii type 1 receptor blockade and angiotensin-converting enzyme...
2874416 - Does angiotensin-ii protect against strokes?
478806 - Intracolonic pressures during barium-enema studies using the single- and double- contra...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of hypertension. Supplement : official journal of the International Society of Hypertension     Volume:  12     ISSN:  0952-1178     ISO Abbreviation:  J Hypertens Suppl     Publication Date:  1994 Jul 
Date Detail:
Created Date:  1994-12-29     Completed Date:  1994-12-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8501422     Medline TA:  J Hypertens Suppl     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  S59-63     Citation Subset:  IM    
Affiliation:
Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use*
Albuminuria / drug therapy*,  etiology*,  urine
Aldosterone / blood
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Blood Pressure / drug effects
Diuretics / therapeutic use*
Female
Glomerular Filtration Rate / drug effects
Humans
Hypertension / complications*,  physiopathology
Male
Middle Aged
Renin / blood
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Diuretics; 52-39-1/Aldosterone; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis.
Next Document:  Angiotensin converting enzyme inhibition and coronary artery disease.